UBS Maintains a 'Buy' on Teva Pharma (TEVA); The Decision's In

UBS maintains a 'Buy' on Teva Pharma (NASDAQ: TEVA) price target of $52.00.

Analyst, Marc Goodman, said the company and investors can breathe a sign of relief as the results have finally come in.

Over the weekend, TEVA reported that U.S. District Court for the Southern District of New York has found in favor of Teva in the Company’s patent infringement lawsuit against Momenta Pharmaceuticals, Inc./Sandoz Inc. (Nasdaq: MNTA) and Mylan Laboratories Inc. (Nasdaq: MYL)/Natco Pharmaceuticals regarding Teva’s relapsing-remitting multiple sclerosis (RRMS) product, COPAXONE.

For an analyst ratings summary and ratings history on Teva Pharma click here. For more ratings news on Teva Pharma click here.

Shares of Teva Pharma closed at $38.10 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Piper Sandler Reiterates Overweight Rating on Estee Lauder (EL), 'F4Q26 Preview'
• Freedom Broker Upgrades Serve Robotics (SERV) to Buy